In Test of Stents, Old Standby Wins Out09/27/10
MONDAY, Sept. 27 (HealthDay News) -- In a head-to-head
comparison of drug-coated stents -- the metal mesh tubes used to
keep clogged arteries open -- the well-established model using the
drug sirolimus came out on top, South Korean researchers
A newer version, one coated with zotarolimus, fell short, the
Coating stents with time-released drugs can help prevent
infection or clogging in stents, but researchers have questioned
the safety and effectiveness of different coatings.
"Drug-coated stents have reduced re-stenosis rates compared to bare metal stents, but require prolonged dual antiplatelet therapy to prevent clotting of the drug-coated stent," said Dr. Gregg Fonarow, an American Heart Association spokesman. "There has been great interest in developing stents coated with alternative drugs and different polymers," he explained.
The study was released online Sept. 27 ahead of print
publication in the Oct. 5 issue of the
Journal of the American College of Cardiology.
In preventing major cardiac events, the researchers found that
zotarolimus-coated stents, the new entry in the field, were less
effective than the sirolimus-eluting stents, but better than stents
coated with paclitaxel.
"Similar to other comparative stent trials, the sirolimus-eluting stent seemed to come out ahead in safety and efficacy," said Fonarow, who is also a cardiology professor at the University of California, Los Angeles.
For the study, a team led by Dr. Duk-Woo Park from the
University of Ulsan College of Medicine and Asan Medical Center in
Seoul randomly assigned 2,645 patients undergoing angioplasty, a
procedure to restore blood flow through the artery, to one of the
After a year, Park's team tallied the number of adverse cardiac
events the patients experienced, including death, heart attack and
the need for a new angioplasty on the same artery in which the
stent was placed.
The researchers found that 10.2 percent of the patients who
received zotarolimus-coated stents suffered a major adverse cardiac
event, compared with 8.3 percent of the patients who received
sirolimus-coated stents and 14.1 percent of those with
The number of heart attacks and deaths was about the same in
each group, but the rate of blood clots in the stents was
significantly lower with sirolimus-eluting stents, Park's team also
"In this large-scale, practical randomized trial, the use of zotarolimus-eluting stents resulted in similar rates of major adverse cardiac events compared with sirolimus-eluting stents and in fewer major adverse cardiac events compared with paclitaxel-eluting stents at 12 months," the researchers concluded in their report.
However, they said a limitation of their study is the one-year
follow-up period, and noted that a longer, ongoing study pitting
zotarolimus-eluting stents against sirolimus-eluting stents will
provide more safety information.
The trial was partially funded by Medtronic, maker of the
Fonarow said the study results can help cardiologists arrive at
treatment decisions. "These studies help to better inform
interventional cardiologists in the optimal choice of drug-eluting
stents for their patients being treated for coronary artery
disease," Fonarow said.
For more information on stents, visit the
U.S. National Library of Medicine.
Copyright © 2010
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.